Unveiling the role of multidrug resistance proteins in hypertension

Hypertension

Volumn 54, Issue 2, 2009, Pages 210-216

  Delou, João Marcos A ^a   Lopes, Aníbal G ^a   Capella, Márcia A M ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN E; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BREAST CANCER RESISTANCE PROTEIN; CARVEDILOL; CELIPROLOL; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCOPROTEIN P; LISINOPRIL; METOPROLOL; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PROPRANOLOL; QUINIDINE; RENIN; RENIN INHIBITOR; SMALL INTERFERING RNA; TALINOLOL; UNINDEXED DRUG; VERLUKAST; VITAMIN K GROUP; ANTIHYPERTENSIVE AGENT;

ABCB1 GENE; ALDOSTERONE BLOOD LEVEL; CYP3A5 GENE; DRUG DISPOSITION; DRUG UPTAKE; GENE; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; MOLECULAR WEIGHT; MORBIDITY; MORTALITY; PHENOTYPE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; ANIMAL; DRUG DELIVERY SYSTEM; DRUG EFFECT; FEMALE; INTESTINE ABSORPTION; MALE; METABOLISM; MOUSE; PHARMACOGENETICS; PHYSIOLOGY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL TRANSPORT; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYPERTENSION; INTESTINAL ABSORPTION; MALE; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEINS; PHARMACOGENETICS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 68549101833     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.129742     Document Type: Review

References (91)

1. Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983-1992.
2. Lawes CM, Vander Hoorn S, Rodgers A. International Society of Hypertension: global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513-1518.
3. Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689-1697.
4. Struthers AD, MacDonald TM. Review of aldosterone-and angiotensin II-induced target organ damage and prevention. Cardiovasc Res. 2004;61:663-670.
5. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem. 1992;267: 24248-24252.
6. Bakos E, Homolya L. Portrait of multifaceted transporter, the multidrug resistance-associated protein 1 (MRP1/ABCC1). Pflugers Arch. 2007;453:621-641.
7. Yamada A, Maeda K, Kamiyama E, Sugiyama D, Kondo T, Shiroyanagi Y, Nakazawa H, Okano T, Adachi M, Schuetz JD, Adachi Y, Hu Z, Kusuhara H, Sugiyama Y. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007;35:2166-2176.
8. Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47:515-531.
9. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9:105-127.
10. Calcagno AM, Kim IW, Wu CP, Shukla S, Ambudkar SV. ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions. Curr Drug Deliv. 2007;4:324-333.
11. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455: 152-162.
12. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258:1650-1654.
13. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A. 1998;95:15665-15670.
14. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, Bates SE. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 1999;59:8-13.
15. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 1998;58:5337-5339.
16. Mizutani T, Masuda M, Nakai E, Furumiya K, Togawa H, Nakamura Y, Kawai Y, Nakahira K, Shinkai S, Takahashi K. Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab. 2008;9:167-174.
17. Kunta JR, Sinko PJ. Intestinal drug transporters: in vivo function and clinical importance. Curr Drug Metab. 2004;5:109-124.
18. Kimura Y, Matsuo M, Takahashi K, Saeki T, Kioka N, Amachi T, Ueda K. ATP hydrolysis-dependent multidrug efflux transporter: MDR1/P-glycoprotein. Curr Drug Metab. 2004;5:1-10.
19. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006;234:4-33.
20. Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett. 2003;140-141:133-143.
21. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990;38:1277-1287.
22. Flens MJ, Zaman GJ, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, de Haas M, Meijer CJ, Scheper RJ. Tissue distribution of the multidrug resistance protein. Am J Pathol. 1996;148: 1237-1247.
23. Huls M, Russel FG, Masereeuw R. The role of ATP binding cassette transporters in tissue defense and organ regeneration. J Pharmacol Exp Ther. 2009;328:3-9.
24. Honig SM, Fu S, Mao X, Yopp A, Gunn MD, Randolph GJ, Bromberg JS. FTY720 stimulates multidrug transporter and cysteinyl leukotrienedependent T cell chemotaxis to lymph nodes. J Clin Invest. 2003;111: 627-637.
25. Dassa E, Bouige P. The ABC of ABCs: a phylogenetic and functional classification of ABC systems in living organisms. Res Microbiol. 2001;152:211-229.
26. Park SW, Lomri N, Simeoni LA, Fruehauf JP, Mechetner E. Analysis of P-glycoprotein-mediated membrane transport in human peripheral blood lymphocytes using the UIC2 shift assay. Cytometry. 2003;53A:67-78.
27. -/- mice. Am J Physiol Gastrointest Liver Physiol. 2005;289:G153-G162.
28. Huls M, Kramers C, Levtchenko EN, Wilmer MJ, Dijkman HB, Kluijtmans LA, van der Hoorn JW, Russel FG, Masereeuw R. P-glycoprotein-deficient mice have proximal tubule dysfunction but are protected against ischemic renal injury. Kidney Int. 2007;72:1233-1241.
29. Ruefli AA, Tainton KM, Darcy PK, Smyth MJ, Johnstone RW. P-glyco-protein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ. 2002;9:1266-1272.
30. Turzanski J, Grundy M, Shang S, Russell N, Pallis M. P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway. Exp Hematol. 2005;33:62-72.
31. Albermann N, Schmitz-Winnenthal FH, Z'graggen K, Volk C, Hoffmann MM, Haefeli WE, Weiss J. Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol. 2005;70:949-958.
32. Neyfakh AA, Serpinskaya AS, Chervonsky AV, Apasov SG, Kazarov AR. Multidrug-resistance phenotype of a subpopulation of T lymphocytes without drug selection. Exp Cell Res. 1989;185:496-505.
33. Cole SP, Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci. 2006;27:438-446.
34. Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem. 1994;269:27807-27810.
35. Osher E, Weisinger G, Limor R, Tordjman K, Stern N. The 5 lipoxygenase system in the vasculature: emerging role in health and disease. Mol Cell Endocrinol. 2006;252:201-206.
36. Evers R, Cnubben NH, Wijnholds J, van Deemter L, van Bladeren PJ, Borst P. Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett. 1997;419:112-116.
37. Echevarria-Lima J, Kyle-Cezar F, Leite DFP, Capella L, Capella MA, Rumjanek VM. Expression and activity of multidrug resistance protein 1 in a murine thymoma cell line. Immunology. 2005;114:468-475.
38. van de Ven R, de Jong MC, Reurs AW, Schoonderwoerd AJ, Jansen G, Hooijberg JH, Scheffer GL, de Gruijl TD, Scheper RJ. Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation. J Immunol. 2006;176:5191-5198.
39. Leite DFP, Echevarria-Lima J, Salgado LT, Capella MAM, Calixto JB, Rumjanek VM. In vivo and in vitro modulation of MDR molecules in murine thymocytes. Int Immunopharmacol. 2006;6:204-215.
40. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001;61: 3458-3464.
41. Huls M, Brown CD, Windass AS, Sayer R, van den Heuvel JJ, Heemskerk S, Russel FG, Masereeuw R. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int. 2008;73:220-225.
42. Krishnamurthy P, Schuetz JD. Role of abcg2/bcrp in biology and medicine. Annu Rev Pharmacol Toxicol. 2006;46:381-410.
43. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, Miyake K, Resau JH, Bates SE. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci. 2000;113:2011-2021.
44. Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y. ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003;278: 22644-22649.
45. Zamek-Gliszczynski MJ, Hoffmaster KA, Humphreys JE, Tian X, Nezasa K, Brouwer KL. Differential involvement of Mrp2 (Abcc2) and Bcrp (Abcg2) in biliary excretion of 4-methylumbelliferyl glucuronide and sulfate in the rat. J Pharmacol Exp Ther. 2006;319:459-467.
46. Ebert B, Seidel A, Lampen A. Identification of BCRP as transporter of benzo[a]pyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis. 2005;26:1754-1763.
47. Ebert B, Seidel A, Lampen A. Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. Toxicol Sci. 2007;96:227-236.
48. Jonker JW, Buitelaar M, Wagenaar E, Van Der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, Schinkel AH. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A. 2002;99:15649-15654.
49. Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, van Veen HW. Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003;278:20645-20651.
50. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res. 2005;65:6640-6650.
51. Enokizono J, Kusuhara H, Sugiyama Y. Effect of breast cancer resistance protein (Bcrp/Abcg2) in the disposition of phytoestrogens. Mol Pharmacol. 2007;72:967-975.
52. Merino G, van Herwaarden AE, Wagenaar E, Jonker JW, Schinkel AH. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver. Mol Pharmacol. 2005;67:1765-1771.
53. Wang H, Zhou L, Gupta A, Vethanayagam RR, Zhang Y, Unadkat JD, Mao Q. Regulation of BCRP/ABCG2 expression by progesterone and 17betaestradiol in human placental BeWo cells. Am J Physiol Endocrinol Metab. 2006;290:E798-E807.
54. van Herwaarden AE, Wagenaar E, Merino G, Jonker JW, Rosing H, Beijnen JH, Schinkel AH. Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol Cell Biol. 2007;27:1247-1253.
55. van Herwaarden AE, Wagenaar E, Karnekamp B, Merino G, Jonker JW, Schinkel AH. Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis. 2006;27:123-130.
56. Morales MM, Capella MA, Sanches MV, Lopes AG, Guggino WB. Modulation of the mdr-1b gene in the kidney of rats subjected to dehydration or a high-salt diet. Pflugers Arch. 2000;439:356-362.
57. Valente RC, Capella LS, Nascimento CR, Braga F, Echevarria-Lima J, Lopes AG, Capella MA. ABCB1 (P-glycoprotein) but not ABCC1 (MRP1) is downregulated in peripheral blood mononuclear cells of spontaneously hypertensive rats. Pflugers Arch. 2008;456:359-368.
58. Kang HJ, Song IS, Lee SS, Yoo MA, Shin JG. Effects of dietary salt on the expression of drug transporters, cytochrome P4503a, and nuclear receptors in rats. Xenobiotica. 2008;38:147-155.
59. Matheny CJ, Ali RY, Yang X, Pollack GM. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metab Dispos. 2004;32:1008-1014.
60. Parker RB, Yates CR, Laizure SC, Weber KT. P-glycoprotein modulates aldosterone plasma disposition and tissue uptake. J Cardiovasc Pharmacol. 2006;47:55-59.
61. Bello-Reuss E, Ernest S, Holland OB, Hellmich MR. Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells. Am J Physiol Cell Physiol. 2000;278: C1256-C1265.
62. Eap CB, Bochud M, Elston RC, Bovet P, Maillard MP, Nussberger J, Schild L, Shamlaye C, Burnier M. CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt. Hypertension. 2007;49:1007-1014.
63. Bochud M, Eap CB, Maillard M, Johnson T, Vollenweider P, Bovet P, Elston RC, Bergmann S, Beckmann JS, Waterworth DM, Mooser V, Gabriel A, Burnier M. Association of ABCB1 genetic variants with renal function in Africans and in Caucasians. BMC Med Genomics. 2008;1:21.
64. Mueller CF, Widder JD, McNally JS, McCann L, Jones DP, Harrison DG. The role of the multidrug resistance protein-1 in modulation of endothelial cell oxidative stress. Circ Res. 2005;97:637-644.
65. Mueller CF, Wassmann K, Widder JD, Wassmann S, Chen CH, Keuler B, Kudin A, Kunz WS, Nickenig G. Multidrug resistance protein-1 affects oxidative stress, endothelial dysfunction, and atherogenesis via leukotriene C4 export. Circulation. 2008;117:2912-2918.
66. Bergen DC, Silberberg D. Nervous system disorders: a global epidemic. Arch Neurol. 2002;59:1194-1196.
67. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
68. Luke MM, O'Meara ES, Rowland CM, Shiffman D, Bare LA, Arellano AR, Longstreth WT Jr, Lumley T, Rice K, Tracy RP, Devlin JJ, Psaty BM. Gene variants associated with ischemic stroke: the cardiovascular health study. Stroke. 2009;40:363-368.
69. Luke MM, Kane JP, Liu DM, Rowland CM, Shiffman D, Cassano J, Catanese JJ, Pullinger CR, Leong DU, Arellano AR, Tong CH, Movsesyan I, Naya-Vigne J, Noordhof C, Feric NT, Malloy MJ, Topol EJ, Koschinsky ML, Devlin JJ, Ellis SG. A polymorphism in the protease-like domain of apolipoprotein (a) is associated with severe coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27: 2030-2036.
70. Mizuarai S, Aozasa N, Kotani H. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer. 2004;109:238-246.
71. Shukla S, Wu CP, Nandigama K, Ambudkar SV. The naphthoquinones, vitamin K3 and its structural analogue plumbagin, are substrates of the multidrug resistance linked ATP binding cassette drug transporter ABCG2. Mol Cancer Ther. 2007;6:3279-3286.
72. Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy. Cancer Metastasis Rev. 2007;26:183-201.
73. Ghanem CI, Gómez PC, Arana MC, Perassolo M, Delli Carpini G, Luquita MG, Veggi LM, Catania VA, Bengochea LA, Mottino AD. Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin. J Pharmacol Exp Ther. 2006;318:1146-1152.
74. Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther. 2003;73:223-231.
75. Naito M, Tsuruo T. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. Cancer Res. 1989;49:1452-1455.
76. Perrotton T, Trompier D, Chang XB, Di Pietro A, Baubichon-Cortay H. (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1. J Biol Chem. 2007;282:31542-31548.
77. Verschraagen M, Koks CH, Schellens JH, Beijnen JH. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res. 1999;40:301-306.
78. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation. 1999;99: 552-557.
79. Cheng J, Kamiya K, Kodama I. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drug Rev. 2001;19: 152-171.
80. Jonsson O, Behnam-Motlagh P, Persson M, Henriksson R, Grankvist K. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glyco-protein activity. Biochem Pharmacol. 1999;58:1801-1806.
81. Kakumoto M, Sakaeda T, Takara K, Nakamura T, Kita T, Yagami T, Kobayashi H, Okamura N, Okumura K. Effects of carvedilol on MDR1-mediated multidrug resistance: comparison with verapamil. Cancer Sci. 2003;94:81-86.
82. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, Kauffmann HM, Schrenk D, Terhaag B, Kroemer HK, Siegmund W. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther. 2000;68:345-355.
83. Karlsson J, Kuo SM, Ziemniak J, Artursson P. Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein. Br J Pharmacol. 1993;110:1009-1016.
84. Neuhoff S, Langguth P, Dressler C, Andersson TB, Regardh CG, Spahn-Langguth H. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites. Int J Clin Pharmacol Ther. 2000;38:168-179.
85. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther. 2003;73:192-198.
86. Bachmakov I, Werner U, Endress B, Auge D, Fromm MF. Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein. Fundam Clin Pharmacol. 2006;20: 273-282.
87. Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D, Dole WP. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. 2008;48:1323-1338.
88. Dieterich H, Kemp C, Vaidyanathan S, Yeh C. Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers. Clin Pharmacol Ther. 2005;79:64.
89. Hasegawa M, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. J Am Soc Nephrol. 2007;18:37-45.
90. Bakos E, Evers R, SinkóE, Váradi A, Borst P, Sarkadi B. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol. 2000;57:760-768.
91. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 2006;34:1247-1254.